Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Essendon, Australia Clinical Trials

A listing of Essendon, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (48) clinical trials

Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

This study will evaluate the safety and efficacy of MK-4280 in combination with pembrolizumab (MK-3475) in participants with hematological malignancies: classical Hodgkin lymphoma (cHL) diffuse large B-cell lymphoma (DLBCL) indolent non-Hodgkin lymphoma (iNHL) The study will have 2 phases: a safety lead-in and an efficacy expansion phase. The recommended Phase ...

Phase

5.02 miles

Learn More »

Study of VIR-2218 in Healthy Volunteers and Patients With Chronic Hepatitis B

This is a phase 1/2 study in which healthy volunteers and subjects with chronic HBV infection will receive VIR-2218 or placebo and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity (only in subjects with chronic HBV).

Phase

5.02 miles

Learn More »

Open-Label Study Of Efficacy and Safety Of AVR-RD-01 for Treatment -Naive Subjects With Classic Fabry Disease

The duration of each subject's participation in this study will be approximately 58 weeks (or 1 year, 6 weeks), comprised of a five study periods (Screening, Baseline, Pre-transplant, Transplant, and Post-transplant Follow-up). During the Screening Period (approximately 4 weeks), written informed consent (and assent, if applicable) will be obtained and ...

Phase

5.26 miles

Learn More »

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements

In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts: EXP-1: ROS1 TKI-nave ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy is allowed EXP-2: 1 Prior ROS1 TKI ROS1+ NSCLC. Disease progression, unresponsive, or intolerant to one prior line of a ROS1 TKI. ...

Phase

5.26 miles

Learn More »

Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors

Blocking antibodies targeting PD-1 have achieved remarkable results in the treatment of many types of tumors. However, it is also worth noting that this therapeutic strategy typically achieves a < 30% objective response rate (ORR) as a monotherapy in patients whose tumors exhibit low positive PD-L1 expression and/or are microsatellite ...

Phase

5.26 miles

Learn More »

A Study of TAS-120 in Patients With Advanced Solid Tumors

Phase 1 Dose Escalation Phase 1 Dose Escalation has been completed as of Dec 2017 Phase 1 Dose Expansion: (CLOSED) Up to approximately 185 patients will be enrolled among the 8 groups as outlined below: Group 1- CCA (iCCA or eCCA) with FGFR2 gene fusions. Group 2- CCA (iCCA or ...

Phase

5.26 miles

Learn More »

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Several groups have explored the possible synergistic interactions between proteasome and HDAC inhibitors in malignant hematopoietic cells. Bortezomib and HDACIs synergistically induce apoptosis, mitochondrial injury (via BAX), ROS generation and oxidative injury in human leukemia and myeloma cells. In view of this evidence, we are proposing a trial to examine ...

Phase

5.26 miles

Learn More »

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors

This is a First-in-Human, open-label, multiple ascending dose escalation and dose expansion study of THOR-707 in adult subjects with advanced or metastatic solid tumors. The objectives of the dose escalation phase are to identify the recommended phase 2 dose (RP2D) of THOR-707 as a monotherapy (Part 1) and in combination ...

Phase

5.26 miles

Learn More »

Safety and Efficacy of SX600 Administered by Lumbosacral Transforaminal Epidural Injection for Radicular Pain

This is a Phase I/II, double-blind, parallel-group, randomized, placebo-controlled multi-centre trial in 180 patients randomized 1:1:1 to receive the IMP (Dexamethasone acetate microspheres for extended-release injectable micro-suspension, SX600 at 12.5 mg or 25.0 mg) or Placebo (0.9% Sodium Chloride for Injection, BP) via transforaminal epidural injection to the lumbosacral epidural ...

Phase

5.26 miles

Learn More »

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic or inoperable locally advanced TNBC who had disease progression during or following first-line metastatic treatment with chemotherapy. The study will be performed in two stages. During ...

Phase

5.38 miles

Learn More »